C6orf35 Inhibitors
Chemical inhibitors of C6orf35 can function by disrupting various signaling pathways that regulate the activity of this protein. Staurosporine is a broad-spectrum kinase inhibitor that can inhibit the activity of multiple protein kinases, which may be involved in the phosphorylation and subsequent regulation of C6orf35. By inhibiting these kinases, Staurosporine can prevent the phosphorylation that is necessary for the proper functioning of C6orf35. Similarly, Bisindolylmaleimide I targets Protein Kinase C (PKC), and if PKC-mediated phosphorylation is crucial for C6orf35 activity, this inhibitor can suppress its function. LY294002 and Wortmannin both target PI3K, another kinase that can regulate various proteins by signaling pathways. If C6orf35 operates downstream of PI3K, inhibition by these chemicals can result in the loss of its functional activity.
Additional inhibitors that target specific components of cellular signaling pathways include Rapamycin, which inhibits the mTOR pathway, a central regulator of cell growth and metabolism that might be upstream of C6orf35. PD98059, U0126, and SB203580 are selective inhibitors of components of the MAPK pathways; PD98059 and U0126 inhibit MEK1/2 while SB203580 inhibits p38 MAPK. If C6orf35 is activated by the MAPK/ERK or the p38 MAPK pathways, these inhibitors can suppress its activation. SP600125, which inhibits JNK, another kinase within the stress-activated MAPK pathways, can also result in the inhibition of C6orf35 if it is regulated by JNK signaling. PP2, an inhibitor of Src family tyrosine kinases, can disrupt the regulation of C6orf35 if Src kinase-mediated phosphorylation is involved in its regulation. Lastly, Gefitinib and Lapatinib are inhibitors of tyrosine kinases associated with the EGFR and HER2 pathways; if C6orf35 is dependent on signaling through these receptors, inhibition by these chemicals can lead to a reduction in C6orf35 activity. Each of these inhibitors can interfere with the phosphorylation state or signaling pathways necessary for the functional activity of C6orf35, thereby leading to its functional inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. C6orf35's function, while not fully characterized, may be influenced by protein phosphorylation. Staurosporine's broad kinase inhibition could lead to decreased activity of kinases that phosphorylate C6orf35, leading to its functional inhibition. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I specifically inhibits Protein Kinase C (PKC). If C6orf35 is regulated by PKC-dependent phosphorylation, this inhibitor would impede the phosphorylation of C6orf35, thus functionally inhibiting its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. PI3K pathways can regulate a variety of proteins. Inhibition of PI3K can lead to functional inhibition of C6orf35 if its activity is contingent on PI3K-mediated signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a central protein in regulating cell growth and metabolism. If C6orf35 functions downstream of or is regulated by the mTOR pathway, Rapamycin would inhibit these signaling pathways, leading to functional inhibition of C6orf35. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another potent inhibitor of PI3K. Similar to LY294002, it would inhibit the PI3K pathway and could functionally inhibit C6orf35 if PI3K signaling is necessary for its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is part of the MAPK/ERK pathway. If C6orf35 is activated by this pathway, inhibition by PD98059 would result in its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK could lead to functional inhibition of C6orf35 if it is regulated by p38 MAPK-dependent signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is part of the stress-activated MAPK pathways. If C6orf35 is regulated by JNK signaling, inhibition by SP600125 would result in functional inhibition of C6orf35. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators of ERK in the MAPK pathway. If C6orf35 activity is dependent on the MAPK pathway, U0126's inhibition of MEK would result in functional inhibition of C6orf35. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. If C6orf35 is regulated by Src kinase-mediated phosphorylation, PP2 could inhibit this regulation and thus functionally inhibit C6orf35. | ||||||